November 1-2, 2011
Masur Auditorium on the NIH Campus
Building 10, Clinical Center
Bethesda, MD
Program Schedule
To view slides from a presenter click the 
icon next to the presentation title.
Tuesday, November 1 |
|
| Moderator: David Stroncek, MD and John O'Shea, MD | |
| 8:30 am - 8:35 am | Welcome and Introductions David Stroncek, MD: National Institutes of Health |
| 8:35 am - 8:45 am | Opening Remarks Joe Palca, PhD: National Public Radio |
| 8:45 am - 9:30 am | Keynote Address Mahendra Rao, MD, PhD: NIH Center for Regenerative Medicine |
| 9:30 am - 10:15 am | Mechanisms of Cellular Reprogramming Gustavo Mostoslavsky, MD, PhD: Boston University School of Medicine |
| 10:15 am - 10:45 am | Break |
| 10:45 am - 11:30 am | Improving Adoptive Cell Transfer-based Immunotherapies in Mice and Men Nick P. Restifo, MD: National Cancer Institute |
| 11:30 am - 12:15 pm | Translation of iPSC Technology: Industrial, Pharmaceutical and Clinical-Grade Cells Peter Flynn, PhD: Fate Therapeutics Inc. |
| 12:15 pm - 1:15 pm | Lunch (On Own) |
| 1:15 pm - 2:00 pm | Enhancing NK Cell Cytoxicity Against Tumors Richard Childs: National Heart, Lung, and Blood Institute, NIH |
| 2:00 pm - 2:45 pm | Role of Dendritic Cells in Immunotherapy of Established (Pre-) Malignant Lesions Cornelis Melief, MD, PhD: Leiden University Medical Center |
| 2:45 pm - 3:15 pm | Regulatory Considerations for Cell Therapies Keith Wonnacott, PhD: Food & Drug Administration |
| 3:15 pm - 3:45 pm | Break |
| 3:45 pm - 4:15 pm | New Methods of Expanding T Cells Mark E. Dudley, PhD: National Cancer Institute, NIH |
| 4:15 pm - 5:00 pm | Evaluation of Biomarkers for T Cell Therapies as Related to Anti-CD19 CAR Therapy Michael Kalos, PhD: University of Pennsylvania |
Wednesday, November 2 |
|
| Moderator: Cornelis Melief, MD, PhD | |
| 8:20 am - 8:30 am | Opening Remarks John Gallin, MD: National Institutes of Health |
| 8:30 am - 9:15 am | Keynote Address: Adoptive Cell Therapy for Metastatic Cancer Steven Rosenberg, MD, PhD: National Cancer Institute, NIH |
| 9:15 am - 10:00 am | Engineered Immunity and Acquired Immunity within an Adoptive Cell Transfer Therapy of Genetically Engineered T Cells for Metastatic Melanoma James Heath, PhD: California Institute of Technology |
| 10:00 am - 10:30 am | Break |
| 10:30 am - 11:15 am | Cell Phenotype for Long Term Persistence after Adoptive Immune Therapy Carolina Berger: Fred Hutchinson Cancer Research Center |
| 11:15 am - 12:00 pm | Identification of Self-renewing, Multipotent CD8+ Memory Stem Cells in Mice and Humans Luca Gattinoni, MD: National Cancer Institute |
| 12:00 pm - 12:30 pm | Clinical Trials from the CITN Martin "Mac" Cheever, MD: Fred Hutchinson Cancer Center; Jeffrey Miller, MD: University of Minnesota; Daniel Powell, PhD: University of Pennsylvania |
| 12:30 pm - 1:00 pm | Closing Question & Answer Discussion Moderator: Cornelis Melief, MD, PhD |
All presentations are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
